Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in
treating patients with acute leukemia or chronic myelogenous leukemia in blast phase.
Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer
cells.